ECSP941144A - Fenoxifenil ciclo-pentenil hidroxiureas - Google Patents

Fenoxifenil ciclo-pentenil hidroxiureas

Info

Publication number
ECSP941144A
ECSP941144A EC1994001144A ECSP941144A ECSP941144A EC SP941144 A ECSP941144 A EC SP941144A EC 1994001144 A EC1994001144 A EC 1994001144A EC SP941144 A ECSP941144 A EC SP941144A EC SP941144 A ECSP941144 A EC SP941144A
Authority
EC
Ecuador
Prior art keywords
compounds
phenoxifenil
pentenil
hidroxiureas
ciclo
Prior art date
Application number
EC1994001144A
Other languages
English (en)
Inventor
Akiyoshi Kawai
Rodney William Stevens
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP941144A publication Critical patent/ECSP941144A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Ciertos compuestos novedosos fenil-sustituídos ciclopentenil hidroxiurea que tienen la capacidad para inhibir la enzima 5-lipoxigenasa y son los isómeros dextrorrotatorios de los compuestos que tienen la fórmula y las sales farmacéuticamente aceptables de los mismos, en la cual R1 es hidrógeno, fluor o cloro; y R2 es hidrógeno o metilo. Estos compuestos son útiles en la prevención, tratamiento o alivio de enfermedades inflamatorias, alergia y enfermedades cardiovasculares en los mamíferos, y como ingrediente activo en las composiciones farmacéuticas para el tratamiento de tales condiciones.
EC1994001144A 1993-08-19 1994-08-17 Fenoxifenil ciclo-pentenil hidroxiureas ECSP941144A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20545393 1993-08-19

Publications (1)

Publication Number Publication Date
ECSP941144A true ECSP941144A (es) 1995-02-27

Family

ID=16507136

Family Applications (1)

Application Number Title Priority Date Filing Date
EC1994001144A ECSP941144A (es) 1993-08-19 1994-08-17 Fenoxifenil ciclo-pentenil hidroxiureas

Country Status (27)

Country Link
US (1) US5792882A (es)
EP (1) EP0720598B1 (es)
JP (1) JP2794343B2 (es)
KR (1) KR0170623B1 (es)
CN (1) CN1077568C (es)
AT (1) ATE171939T1 (es)
AU (1) AU674776B2 (es)
BR (1) BR9407314A (es)
CA (1) CA2169066C (es)
CO (1) CO4230229A1 (es)
CZ (1) CZ288358B6 (es)
DE (1) DE69413831T2 (es)
DK (1) DK0720598T3 (es)
EC (1) ECSP941144A (es)
EG (1) EG20530A (es)
ES (1) ES2121218T3 (es)
FI (1) FI114466B (es)
IL (1) IL110628A (es)
MY (1) MY111140A (es)
NO (1) NO305595B1 (es)
NZ (1) NZ269849A (es)
PE (1) PE57194A1 (es)
PL (1) PL176223B1 (es)
RU (1) RU2125987C1 (es)
TW (2) TW448144B (es)
WO (1) WO1995005360A1 (es)
ZA (1) ZA946253B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253564T1 (de) * 1994-06-27 2003-11-15 Millenium Pharmaceuticals Inc Verbindungen und verfahren zur behandlung von cardiovaskulären, inflammatorischen und das immunsystem betreffende erkrankungen
WO1996015106A1 (en) * 1994-11-10 1996-05-23 Pfizer Pharmaceuticals Inc. Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas as 5-lipoxygenase inhibitors
WO1996016054A1 (en) * 1994-11-18 1996-05-30 Pfizer Pharmaceuticals Inc. Cycloalkenyl-n-hydroxyureas
EP1745774A3 (en) 1997-08-11 2007-04-11 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US6121323A (en) * 1997-12-03 2000-09-19 3M Innovative Properties Company Bishydroxyureas
ATE495148T1 (de) 2004-12-02 2011-01-15 Amorepacific Corp Die produktion von tnf-alpha inhibierenden 2- cyclopenten-1-onoximderivate
KR101494488B1 (ko) * 2007-12-03 2015-02-24 (주)아모레퍼시픽 2-사이클로펜텐-1-온 옥심 유도체를 유효성분으로 포함하는 지방대사질환 예방 및 치료용 약학 조성물
HUE027598T2 (en) 2009-04-03 2016-10-28 Hoffmann La Roche Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses
US8512464B2 (en) * 2009-12-02 2013-08-20 3M Innovative Properties Company Functionalized zirconia nanoparticles and high index films made therefrom

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
US5026729A (en) * 1987-02-10 1991-06-25 Abbott Laboratories Lipoxygenase inhibiting compounds
NZ232350A (en) * 1989-02-03 1992-04-28 Wellcome Found N-(1-methyl-3-((halophenoxy)phenyl)prop-2-en-1-yl)-n-hydroxyurea derivatives and pharmaceutical compositions
US5037853A (en) * 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
US5120752A (en) * 1989-12-28 1992-06-09 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
GB9025514D0 (en) * 1990-11-23 1991-01-09 Wellcome Found Anti-inflammatory compounds
JP3007138B2 (ja) * 1990-11-27 2000-02-07 ファイザー製薬株式会社 新規なヒドロキサム酸とｎ―ヒドロキシ尿素誘導体およびそれらの組成物
JPH06256285A (ja) * 1990-12-11 1994-09-13 Pfizer Pharmaceut Co Ltd ヒドロキサム酸誘導体およびその用途
US5130485A (en) * 1991-04-23 1992-07-14 Eli Lilly And Company N-hydroxy-N-(3-(2-substituted phenyl)prop-2-enyl)ureas and thioureas useful as 5-lipoxygenase inhibiting agents
US5149097A (en) * 1991-05-01 1992-09-22 Tonello John H Crossword puzzle aid
JPH05163229A (ja) * 1991-12-13 1993-06-29 Pfizer Pharmaceut Co Ltd 新規なシクロプロピル誘導体
JPH05294921A (ja) * 1992-04-17 1993-11-09 Pfizer Pharmaceut Co Ltd 新規なフェニル置換シクロアルキル尿素誘導体および組成物

Also Published As

Publication number Publication date
ES2121218T3 (es) 1998-11-16
CO4230229A1 (es) 1995-10-19
PE57194A1 (es) 1995-02-07
MY111140A (en) 1999-08-30
AU674776B2 (en) 1997-01-09
NO960631D0 (no) 1996-02-16
AU7350994A (en) 1995-03-14
CN1077568C (zh) 2002-01-09
FI943799L (fi) 1995-02-20
WO1995005360A1 (en) 1995-02-23
NO960631L (no) 1996-02-16
TW418089B (en) 2001-01-11
KR960703845A (ko) 1996-08-31
BR9407314A (pt) 1996-04-16
CA2169066C (en) 1999-06-22
CN1129440A (zh) 1996-08-21
EG20530A (en) 1999-07-31
ATE171939T1 (de) 1998-10-15
EP0720598A1 (en) 1996-07-10
RU2125987C1 (ru) 1999-02-10
US5792882A (en) 1998-08-11
NZ269849A (en) 1997-10-24
TW448144B (en) 2001-08-01
DE69413831D1 (de) 1998-11-12
JP2794343B2 (ja) 1998-09-03
PL176223B1 (pl) 1999-05-31
CA2169066A1 (en) 1995-02-23
NO305595B1 (no) 1999-06-28
PL313037A1 (en) 1996-05-27
FI943799A0 (fi) 1994-08-18
JPH08511031A (ja) 1996-11-19
FI114466B (fi) 2004-10-29
IL110628A0 (en) 1994-11-11
DE69413831T2 (de) 1999-02-25
KR0170623B1 (ko) 1999-03-30
ZA946253B (en) 1996-02-19
CZ288358B6 (en) 2001-05-16
EP0720598B1 (en) 1998-10-07
DK0720598T3 (da) 1999-06-21
CZ48396A3 (en) 1996-07-17
IL110628A (en) 1998-12-27

Similar Documents

Publication Publication Date Title
ES2069410T3 (es) Nuevos derivados del acido hidroxamico y n-hidroxiurea y su uso.
PY0125983A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
PT1175214E (pt) Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico
PA8486001A1 (es) Composiciones de celecoxib
NO2017045I1 (no) Farmasøøytisk preparat inneholdende 2-(2-nitro-4-ifluormetylbenzoyl)-1,3-cykloheksandion eller et farmasøytisk godtagbart salt derav
BRPI0411825B8 (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica
ES2189824T3 (es) Antagonistas no peptidicos del receptor de taquiquininas.
MX2017010220A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
ES2119124T3 (es) Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso.
CY1111446T1 (el) Συνθεσεις περιλαμβανουσες κρυσταλλικη trans- (+/-)-δελτα-9-τετραϋδροκανναβινολη
AR038628A1 (es) Composicion oftalmica
MX9400800A (es) Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion.
AR033151A1 (es) Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
CL2008003027A1 (es) Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades.
CO2024017422A2 (es) Composiciones y métodos para inhibir la expresión de serina proteasa transmembrana 6 (tmprss6)
ES2121218T3 (es) Fenoxifenilciclopentenilhidroxiureas.
CO5261531A1 (es) Derivados de pleuromutilina y valnemulina usados para la fabricacion de un medicamento en el tratamiento transdermico de infecciones bacterianas en humanos y animales y composicion que los contiene
ES2138211T3 (es) N-hidroxiureas como agentes antiinflamatorios.
ES2063578T3 (es) Derivados del acido hidroxamico y de n-hidroxiurea inhibidores de la lipoxigenasa.
MX2025005720A (es) Inhibidores de la tirosina-cinasa 2 (tyk2)
ES2059204T3 (es) Derivados del acido hidroxamico inhibidores de lipoxigenasa.
PA8579701A1 (es) Profarmaco inhibidor de beta-lactamasa
ES2139746T3 (es) Heteroaril cicloalquenil hidroxiureas.
CO5271694A1 (es) Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion